1. Loganin substantially ameliorates molecular deficits, pathologies and cognitive impairment in a mouse model of Alzheimer’s disease
- Author
-
Shupeng Li, Kaiwu He, Fengzhu Xie, Li Zhou, Lulin Nie, Liangyu Zou, Xifei Yang, Shifeng Xiao, Jia Xu, Chen Yang, Kaiqin Zhang, and Jianjun Liu
- Subjects
Aging ,Proteome ,Hippocampus ,Mice, Transgenic ,Disease ,Pharmacology ,Neuroprotection ,Mice ,chemistry.chemical_compound ,Western blot ,Alzheimer Disease ,Morris Water Maze Test ,medicine ,Animals ,Cognitive Dysfunction ,Iridoids ,loganin ,Pathological ,cognitive impairment ,medicine.diagnostic_test ,Loganin ,business.industry ,Cell Biology ,Alzheimer's disease ,Cortex (botany) ,Disease Models, Animal ,Neuroprotective Agents ,chemistry ,2D-DIGE ,Immunohistochemistry ,Female ,business ,Research Paper - Abstract
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease threatening the health of the elderly, but the available therapeutic and preventive drugs remain suboptimal. Loganin, an iridoid glycoside extracted from Cornus officinalis, is reported to have anti-inflammatory and memory-enhancing properties. This study is aimed to explore the influence of loganin on cognitive function in 3xTg-AD mice and the underlying mechanism associated with its neuroprotection. According to the results of behavioral tests, we found that administration of loganin could significantly alleviate anxiety behavior and improve memory deficits of 3xTg-AD mice. Furthermore, immunohistochemical analysis displayed that there were decreased Aβ deposition in the hippocampus and cortex of 3xTg-AD mice treated with loganin compared with the control mice. Importantly, the Aβ-related pathological change was mainly involved in altering APP expression and processing. And loganin was also found to reduce the levels of phosphorylated tau (i.e. pTauS396 and pTauS262) in 3xTg-AD mice. By performing 2D-DIGE combined with MALDI-TOF-MS/MS, we revealed 28 differentially expressed proteins in the 3xTg-AD mice treated with loganin compared with the control mice. Notably, 10 proteins largely involved in energy metabolism, synaptic proteins, inflammatory response, and ATP binding were simultaneously detected in 3xTg-AD mice compared to WT mice. The abnormal changes of energy metabolism (PAGM1 and ENO1), synaptic proteins (SYN2 and Cplx2), inflammatory response (1433Z) were verified by western blot. Overall, our study suggested that loganin could be used as a feasible candidate drug to ameliorate molecular deficits, pathologies and cognitive impairment for prevention and treatment of AD.
- Published
- 2021
- Full Text
- View/download PDF